FOLH1 and neoplasm: PSMA-targeted RPT has been shown to increase overall survival compared with standard-of-care treatment in patients with mCRPC (3), but a need remains for next-generation radiopharmaceuticals that can provide improved tumor uptake while minimizing uptake to the kidneys, which remain one of the most significant organs at risk.